Telehealth has been around for years in the United States, but it was not until the coronavirus disease 2019 (COVID-19) pandemic that it became so widely used.
Telehealth has been around for years in the United States, but it was not until the coronavirus disease 2019 (COVID-19) pandemic that it became regularly used. The growth of telehealth was fueled by the inability to see patients in person at the beginning of the pandemic and a move by the government to temporarily relax regulations.
Joseph Kvedar, MD, president of the American Telemedicine Association, professor of Dermatology at Harvard Medical School, co-chair of the American Medical Association's Digital Medicine Payment Advisory Group, and editor-in-chief of npj Digital Medicine, explained that some of those relaxations might continue on after the COVID-19 pandemic passes, but some may get rolled back.
In conversation with Patricia Salber, MD, MBA, of The Doctor Weighs In, Kvedar also discussed how breakthroughs in technology have helped make virtual visits possible, the future of telehealth, and more.
Listen above or through one of these podcast services:
Learn more:
Contributor: Telehealth Claim Lines Increased 4132% Nationally From June 2019 to June 2020
Continuation of Routine Screenings, Care Is Crucial During COVID-19 Pandemic
ACR Position Statement Supports Use of Telemedicine After COVID-19 Crisis
Which Telehealth Changes Will Become Permanent? Hints May Come Next Month
In-person Visits Are Invaluable, but Telehealth Is Here to Stay
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen